Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 October 2007

Ann Rheum Dis. Published Online First: 9 March 2007. doi:10.1136/ard.2006.066084
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism.

Extended Report

Circulating levels of the chemokine CCL18, but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis

Antoine WT van Lieshout 1, Jaap Fransen 1, Marcel Flendrie 1, Agnes MM Eijsbouts 2, Frank HJ van den Hoogen 1, Piet LCM van Riel 1 and Timothy RDJ Radstake 1*

1 RUNMC, Netherlands
2 St. Maartenskliniek, Netherlands

* To whom correspondence should be addressed. E-mail: t.radstake{at}reuma.umcn.nl.

Accepted 27 February 2007


Abstract

Background: Antigen presenting cells (APC) and T cells are considered to play a significant role in the pathogenesis of rheumatoid arthritis (RA). CCL18 and CXCL16 are two chemokines that facilitate T cell attraction by APC, of which a role in the pathogenesis of RA has been suggested.

Objective: To compare the circulating levels of CXCL16 and CCL18 in RA with controls and to investigate the relation of CXCL16 and CCL18 with RA disease activity and joint damage.

Methods: Circulating CCL18 and CXCL16 levels were determined in 61 RA patients with a follow-up of 6 years and a group of 41 healthy controls with ELISA. Chemokine levels were correlated with demographical data, disease activity (DAS28) and joint damage (modified Sharp score). In addition, serum CCL18 and CXCL16 levels from a cohort of 44 RA patients treated with anti TNF-alpha were correlated with disease activity.

Results: CCL18 levels in serum were significantly elevated in RA patients compared to controls, while serum CXCL16 levels were not. In contrast to CXCL16, serum CCL18 was positively correlated with disease activity. Both CCL18 and CXCL16 levels decreased upon treatment with anti TNF-alpha. Neither CCL18 nor CXCL16 correlated with joint damage and progression.

Conclusion: Here we show, for the first time, that circulating CCL18 and not CXCL16 levels are elevated in RA patients as compared to controls and correlate with disease activity in RA. More knowledge regarding the regulation and function of both CCL18 and CXCL16 is essential to value their role in RA.

Keywords: anti TNF-alpha, ccl18, chemokines, cxcl16, rheumatoid arthritis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • van Lieshout, A W T, van der Voort, R, Toonen, L W J, van Helden, S F G, Figdor, C G, van Riel, P L C M, Radstake, T R D J, Adema, G J (2009). Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann Rheum Dis 68: 1036-1043 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs